Alopecia Areata
Sun Pharma revealed data at the 2024 Fall Clinical Dermatology Conference (held between October 24th – 27th, 2024, in Las Vegas, Nevada) regarding the efficacy of LEQSELVI (deuruxolitinib), its treatment for alopecia areata (AA). The data includes collated results from open-label extension studies that have monitored LEQSELVI used for up to 68 weeks. Improvements were…
Read More
The US Food and Drug Administration (FDA) has recently approved deuruxolitinib, an oral Janus Kinase (JAK) inhibitor developed by Sun Pharma, for treating severe alopecia areata in adults. What is Deuruxolitinib? Deuruxolitinib, sold under the brand name Leqselvi, is an oral JAK inhibitor that selectively targets JAK1 and JAK2, proteins involved in the immune signaling…
Read More
An overview of treatments for pattern baldness and alopecia which will be in the clinical trial stage during 2023. Androgenetic Alopecia Trials Chong Kun Dang Pharmaceutical – We begin the list with a newcomer, previously unannounced. CKD-843 is a new injectable drug being trialed in “alopecia” by the Chong Kun Dang (CKD) Pharmaceutical company of Seoul,…
Read More
In this article we will cover the most prominent therapeutic candidates in the alopecia areata treatment industry in 2023. Frontrunners To Market In June 2022, Eli Lilly/Incyte received the FDA’s first ever approval for a systemic treatment for alopecia areata with their drug Olumiant. Alopecia areata, an auto-immune disorder which results in patchy and sometimes…
Read More
I’m pleased to share with you all a startup which is a little bit “outside the box” from the usual companies you’d see on Follicle Thought. Today’s topic of interest, Birch BioMed, is based in Vancouver, Canada and was birthed on the campus of the University of British Columbia. The company’s prize clinical candidate is…
Read More
According to its latest press release, Aclaris Therapeutics will be launching a phase 2 trial for the use of JAK inhibitors in androgenic alopecia (pattern hair loss) within the next few months. Here’s the line item from the press release about Aclaris’ trial in androgenic alopecia. AGA-201 Topical – a planned Phase 2 open-label clinical trial…
Read More
This article is a news feed containing brief updates of the most important hair growth treatment and hair loss cure news. It’s updated several times a week.
Read More
Located within the biotech cluster which is Cambridge, Massachusetts sits a contemporary R&D platform, the LEO Science & Tech Hub. The Science & Tech Hub is an innovation unit of the international dermatology-focused LEO Pharma company. The Tech Hub seeks to engage with and bolster new technology which may offer solutions to dermatological and other…
Read More
Just when we thought we knew of every company in the world working on hair growth treatments… With all of the scientific articles on hair biology that continually get published from Asian establishments there was bound to be a few companies springing up at some point. I’m happy to say I’ve got 4 new companies…
Read MoreHello everyone, and welcome to another edition of Weekly Thoughts. It has been a little while since my last check in with you all. You can chalk it up to a busy schedule and the fact that there hasn’t been too much significant news in the hair growth treatment world recently. As always, there are…
Read More